LIVER FIBROSIS TREATMENT MARKET ANALYSIS

Liver Fibrosis Treatment Market, by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by Distribution Channel (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2320
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Liver Fibrosis Treatment Market: Key Developments

In December 2021, Beijing Continent Pharmaceutical Co, Ltd., a pharmaceutical company, had carried out Phase II clinical trial successfully for Hydronidone capsules, and was promoted for phase 3 clinical trial in January 2022. The phase 3 clinical trial studies for Hydronidone capsules are still ongoing and expected to complete study of clinical trial in June 2024.